טוען...

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-designated drug, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 (PD-L1), as determin...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Oncologist
Main Authors:	Sul, Joohee, Blumenthal, Gideon M., Jiang, Xiaoping, He, Kun, Keegan, Patricia, Pazdur, Richard
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	AlphaMed Press 2016
נושאים:	Regulatory Issues: FDA
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4861368/ https://ncbi.nlm.nih.gov/pubmed/27026676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0498
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

פריטים דומים